Literature DB >> 12064638

Ecstasy (MDMA) deaths in New York City: a case series and review of the literature.

James R Gill1, Jonathan A Hayes, Ian S deSouza, Elizabeth Marker, Marina Stajic.   

Abstract

MDMA ("ecstasy") has gained renewed popularity as a drug of abuse. To access the epidemiology and causes of death of MDMA-positive fatalities, all deaths investigated by the OCME that tested positive for MDMA (22 deaths) between January 1997 and June 2000 were reviewed. There were three deaths in each 1997 and 1998, eleven in 1999, and five in the first part of 2000. Of these 22 deaths, 13 were due to acute drug intoxications, 7 due to mechanical injury (blunt trauma, gunshot wounds), and 2 due to a combination of natural disease and acute drug intoxication. Evidence of recent opiate and/or cocaine use was found in 7 of the acute intoxication deaths and in none of the traumatic or combination natural/intoxication deaths. The race of all decedents was White between the ages of 17-41 years, and 18 of 22 were men.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064638

Source DB:  PubMed          Journal:  J Forensic Sci        ISSN: 0022-1198            Impact factor:   1.832


  7 in total

1.  Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Authors:  H R Sumnall; L Jerome; R Doblin; M C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

2.  An announced suicide with ecstasy.

Authors:  Kathrin Libiseller; Marion Pavlic; Petra Grubwieser; Walter Rabl
Journal:  Int J Legal Med       Date:  2005-09-21       Impact factor: 2.686

3.  "Ecstasy" associated deaths: what is a fatal concentration ? Analysis of a case series.

Authors:  C M Milroy
Journal:  Forensic Sci Med Pathol       Date:  2011-01-25       Impact factor: 2.007

Review 4.  A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities.

Authors:  Fabrizio Schifano
Journal:  Psychopharmacology (Berl)       Date:  2003-12-13       Impact factor: 4.530

5.  Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  J Clin Psychopharmacol       Date:  2008-08       Impact factor: 3.153

6.  Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.

Authors:  Mireia Segura; Magí Farré; Simona Pichini; Ana M Peiró; Pere N Roset; Ariel Ramírez; Jordi Ortuño; Roberta Pacifici; Piergiorgio Zuccaro; Jordi Segura; Rafael de la Torre
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

7.  Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.

Authors:  Andrea E Steuer; Corina Schmidhauser; Eva H Tingelhoff; Yasmin Schmid; Anna Rickli; Thomas Kraemer; Matthias E Liechti
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.